News for PDS Biotechnology Corporation (PDSB)

PDS Biotechnology (PDSB) announces three clinical trial presentations at the 2025 ASCO Annual Meeting. Key focus on Versamune® HPV (PDS0101) for HPV-re

**media[603423]**

\nUpdate on American Association for Cancer Research Annual Meeting 2025 presentation\n\nPRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Co

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ETCompany ParticipantsTom Johnson - LifeSci...

Updated time slot of 11:00 AM CT on Friday, March 28, 2025 PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( PDSB) (”œPDS

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts.

PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( PDSB) (”œPDS Biotech” or the ”œCompany”), a late-stage immunotherapy

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced t...

PDS Biotechnology received U.S. FDA clearance for its Investigational New Drug application to treat metastatic colorectal carcinoma. Read more here.

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets M

PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( PDSB) (”œPDS Biotech” or the ”œCompany”), a late-stage immunotherapy

**media[560192]**

$11 Million Upfront with up to an Additional $11 Million of Aggregate Gross Proceeds Upon the Cash Exercise in Full of the Warrants PRINCETON, N.J., Feb. 27,

Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers ”“ Initiation of Phase 3 trial in HPV16-positive HNSCC

**media[485339]**

PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) (

Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation PRINC

The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.